SCHEMBL1808357

SCHEMBL1808357

COC(=O)C(C)COc1ccc(CC(O)=S)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.44
LMNA P02545 3/20 0.44
ADRB2 P07550 2/20 0.44
ADRB1 P08588 2/20 0.44
PMP22 Q01453 2/20 0.44
CNR1 P21554 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
KDM4E B2RXH2 1/20 0.44
CYP1A2 P05177 1/20 0.44
GLA P06280 1/20 0.44
CYP3A4 P08684 1/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
THPO P40225 1/20 0.44
BLM P54132 1/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3717529 0.81 LOXL2 (0.51) TDP1LMNAADRB2ADRB1PMP22
SCHEMBL12384285 0.80 MTNR1A (0.58) LMNAADRB2ADRB1MAPTKMT2A
SCHEMBL22651641 0.80 ALDH1A1 (0.51) ADRB2ADRB1TSHRMAPTALDH1A1
SCHEMBL7045834 0.78 MAPT (0.54) LMNACYP1A2MAPTKMT2AALDH1A1
SCHEMBL7749771 0.77 MAPT (0.51) TDP1KDM4ETSHRMEN1MAPT
SCHEMBL11780675 0.75 ALDH1A1 (0.50) LMNAADRB2ADRB1TSHRMAPT
SCHEMBL16379337 0.74 ALDH1A1 (0.50) LMNAALDH1A1PPARDPPARA
SCHEMBL27697302 0.72 MAPT (0.41) LMNAADRB2ADRB1CYP1A2TSHR
SCHEMBL3716440 0.72 MAPT (0.47) TDP1LMNAMEN1MAPTALOX12
SCHEMBL1811746 0.72 LOXL2 (0.59) TDP1TSHRMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801108-B9 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2013-11-20 EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 EP disclosed
CN-101014580-B Morpholine compound MITSUBISHI PHARMA CORP 2011-05-04 CN disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 US disclosed
CN-101014580-A Morpholine compound MITSUBISHI PHARMA CORP (JP) 2007-08-08 CN disclosed
EP-1801108-A1 MORPHOLINE COMPOUND Mitsubishi Pharma Corporation (JP) 2007-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265257-A1 Morpholine Compound CCR3, CCR1, CCR4 TDP1 3997/4885LMNA 2526/4885ADRB2 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.